Clearside Biomedical Inc (CLSD): Rasio rega marang pendapatan

The price/sales ratio displayed on this GURU.Markets chart demonstrates the current 0.70. This trend reflects stable licensing royalties that generate a consistent cash flow. Clearside Biomedical (CLSD) bases its business foundation on US R&D centers developing ocular treatments. The company gains a competitive edge through the SCS microinjector, which precisely delivers drugs to the posterior wall of the eye while minimizing negative effects.

CLSD Multiplikator P/S Clearside Biomedical (04.07.2022 - 13.12.2025)

Rincian metrik lan analitis perusahaan Clearside (CLSD)

- rega pasar lan target rega analis:

Kutipan saham clearsidebio.com|CLSD - Bagan rega target

- data kapitalisasi bursa:

Nilai pasar Clearside|CLSD - Nilai Perusahaan

- statistik nilai buku emiten:

Nilai Aset Bersih saben Saham Clearside Biomedical|CLSD - Kapitalisasi Buku|Rasio Kapitalisasi Pasar marang Nilai Buku clearsidebio.com|CLSD - Aset Agregat Perusahaan

- statistik kawajiban utang lan likuiditas:

Rasio Kabeh Utang marang Dana Pribadi Clearside Biomedical|CLSD - Utang jangka dawa marang ekuitas|Koefisien utang jangka cendhak marang modal Clearside Corp|CLSD - Gunggung utang perusahaan|Utang-utang marang aset resik Clearside|CLSD - Utang jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Clearside Biomedical|Likuiditas darurat clearsidebio.com

- data bathi lan kelipatan valuasi:

CLSD - Penghasilan resik|Penghasilan resik sing dikarepake Clearside Biomedical|CLSD - Pangali P/E|Rega marang bathi mangsa ngarep Clearside Biomedical Inc|CLSD - Pangali PEG|Rasio total nilai perusahaan marang bathi operasional sadurunge panyusutan Clearside|CLSD - Bathi sadurunge mbayar bunga, pajak, lan amortisasi|Bathi resik saben siji saham sajrone rolas wulan pungkasan Clearside Biomedical|CLSD - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi resik saben saham taun-ka-taun sajrone 12 wulan pungkasan clearsidebio.com|CLSD - Wutah bathi ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Clearside Biomedical

- rincian pendapatan lan dodolan emiten:

CLSD - Pendapatan lan volume dodolan|Prakiraan pendapatan perusahaan clearsidebio.com|CLSD - Multiplikator P/S|Rasio kapitalisasi marang dodolan sing dikarepake Clearside

Analisis umum perusahaan:CLSD, clearsidebio.com

For Clearside Biomedical (CLSD), which develops precision drug delivery systems for the posterior segment of the eye, the company's price-to-sales ratio serves as a gauge of market expectations. This coefficient compares the current business value with its annual sales volume. The calculation is based on dividing the total market capitalization by aggregate revenue, revealing the premium paid per unit of sales. Exceeding the indicator's historical highs may signal an overvaluation of assets ahead of a cycle shift.

Perusahaan pesaing

Kapitalisasi marang pendapatan alcon.com ALC|Rasio rega marang pendapatan Bausch + Lomb BLCO|Glaukos Corp - Rasio rega marang pendapatan|Apellis Pharmaceuticals Inc - Multiplikator P/S|Rega marang dodolan Belite Bio, Inc|OCUL: Multiplikator P/S|harrowinc.com (HROW) - Multiplikator P/S|Rasio rega marang pendapatan Viridian Therapeutics, Inc.|LENZ: Rasio kapitalisasi pasar marang pendapatan|Rasio rega marang pendapatan Oculis AG (OCS)|Koefisien rega marang pendapatan EyePoint Corp|Multiplikator P/S KOD (Kodiak Sciences Inc.)|Koefisien rega marang pendapatan Aldeyra Therapeutics Inc. (ALDX)|Kala Pharmaceuticals - Multiplikator P/S|IRD (Opus Genetics Inc) - Rasio kapitalisasi marang pendapatan|OKYO: Multiplikator P/S|Rega marang dodolan Adverum Biotechnologies, Inc. (ADVM)|Kapitalisasi marang pendapatan OTLK|NBY: Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S KPRX|Rasio rega marang pendapatan ALIM (alimerasciences.com)|Multiplikator P/S EYEN (Eyenovia)|Koefisien rega marang pendapatan Guardion Health (GHSI)|OCUP - Rasio rega marang pendapatan|Rega marang dodolan opthea.com